Where Freeline Therapeutics Stands With Analysts
Portfolio Pulse from Benzinga Insights
Freeline Therapeutics (NASDAQ:FRLN) has received 2 bullish and 2 indifferent ratings from analysts in the last quarter. The company's average price target has increased by 77.27% over the past month, with a current average of $9.75, a high of $15.00, and a low of $4.00.
October 18, 2023 | 9:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Freeline Therapeutics has received mixed ratings from analysts, with an increase in the average price target over the past month.
The mixed ratings from analysts indicate uncertainty about the company's performance. However, the significant increase in the average price target suggests a positive outlook, which could potentially lead to an increase in the stock price.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100